Related Experiment Video
Updated: Sep 10, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Noncanonical Pathways of Proteasome Inhibition in HPV-Negative Head & Neck Cancer
Hye-Yeon Lee1, Ji-Yeong Kim1, Zhiyong Wang2
1Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Abstract:
Carfilzomib, a second-generation proteasome inhibitor approved for the treatment of multiple myeloma, is a highly potent and selective inhibitor of the CT-L activity of the i20S proteasome. Several studies have shown that carfilzomib (CFZ) can bypass resistance to bortezomib; however, its impact on squamous cell carcinoma of the head and neck is not well understood. This study aimed to evaluate the anticancer potential of CFZ in head and neck cancer cells (HNSCC) by examining its effects on proliferation, apoptosis, and the underlying mechanisms in both HPV-positive and HPV-negative HNSCC. In Vitro validation of CFZ showed an IC50 that was more than fourfold lower in HPV-negative CAL-27 than other HNSCC cell lines. In addition, CFZ inhibited p-Akt and p-S6 and activated p21, which increased growth inhibition and apoptosis in CAL-27 cells. In mice bearing xenografted HPV-negative CAL-27 cells, we confirmed that CFZ reduced tumor growth. Collectively, the cytotoxic effects induced by CFZ involve cell growth inhibition and apoptosis via the PI3K/AKT/mTOR and p21 signaling pathways. This suggests that CFZ is a novel therapeutic agent that can overcome the existing cisplatin resistance used in the treatment of HPV-negative HNSCC.
Insights
Carfilzomib (CFZ) effectively inhibits head and neck cancer cell growth and induces apoptosis, particularly in HPV-negative HNSCC. This proteasome inhibitor shows promise in overcoming cisplatin resistance, suggesting a new therapeutic avenue.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Carfilzomib (CFZ) is a proteasome inhibitor used for multiple myeloma.
- Its efficacy in head and neck squamous cell carcinoma (HNSCC), especially HPV-negative types, is not well-established.
- Understanding CFZ's impact on HNSCC is crucial for developing new treatment strategies.
Purpose of the Study:
- To evaluate the anticancer potential of carfilzomib (CFZ) in HPV-positive and HPV-negative head and neck cancer cells (HNSCC).
- To investigate the mechanisms underlying CFZ's effects on HNSCC proliferation and apoptosis.
- To assess CFZ's efficacy in overcoming cisplatin resistance in HPV-negative HNSCC.
Main Methods:
- In vitro assessment of CFZ's IC50 in various HNSCC cell lines.
- Analysis of signaling pathways (PI3K/AKT/mTOR, p21) affected by CFZ treatment.
- In vivo evaluation of CFZ's effect on tumor growth in mice bearing xenografted HPV-negative HNSCC cells.
Main Results:
- CFZ demonstrated significantly higher potency (lower IC50) in HPV-negative CAL-27 HNSCC cells compared to other HNSCC lines.
- CFZ inhibited Akt/mTOR signaling (p-Akt, p-S6) and activated p21, leading to growth inhibition and apoptosis in CAL-27 cells.
- CFZ treatment reduced tumor growth in mice with xenografted HPV-negative CAL-27 tumors.
Conclusions:
- Carfilzomib induces cytotoxic effects in HNSCC, primarily through cell growth inhibition and apoptosis via the PI3K/AKT/mTOR and p21 pathways.
- CFZ demonstrates potential as a therapeutic agent for HPV-negative HNSCC, offering a strategy to overcome cisplatin resistance.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity
The JAK-STAT Signaling Pathway
The Extrinsic Apoptotic Pathway
Mechanisms of Retrovirus-induced Cancers

